While some studies suggest that TGF-β2, rather than TGF-β1, is a biomarker for poor prognosis in ovarian cancer [34], Liu et al. found that TGF-β1 may increase resistance to apoptosis in endometriotic tissue, promote survival by decreasing immune cell activity, and facilitate cell migration and invasion [35]. This evidence concerns the gene TGFB2 and ovarian carcinoma.